PlexBio is committed to the holistic care of cancer patients, begins with early detection of cancers and diseases, providing solution to precise treatment for the patients, and at the same, not to reside at the diagnosis and treatment stages, PlexBio determines to make monitoring tumor status prior and after the implementation of the treatment available, thus, offers a full scope of cancer management to the patients.

 The new diagnostic πCode™ technology platform developed by PlexBio is able to rapidly determine the status of a wide range of somatic gene mutations or gene rearrangements typically seen in various cancers, and is applicable in a wide range of scientific and research fields In combination with SelectAmp, a mutation-enriching PCR amplification technique that dramatically increases mutation detection sensitivities, the new analytic approach presented by PlexBio holds strong promise for use with ‘liquid biopsy’ samples.